Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 4/20 | 0.67 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.66 |
| ▸ | ELANE | P08246 | 4/20 | 0.60 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.59 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.59 |
| ▸ | MC4R | P32245 | 1/20 | 0.58 |
| ▸ | MC1R | Q01726 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CTSG | P08311 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.57 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412265 | 0.97 | KLKB1 (0.63) | KLKB1EPHA2ELANEKCNA3KCNA1 | |
| SCHEMBL29412281 | 0.94 | ELANE (0.62) | KLKB1EPHA2ELANEKCNA3KCNA1 | |
| Circulin A SCHEMBL29508768 | 0.85 | ELANE (0.73) | KLKB1EPHA2ELANECHRNA7 | |
| Vitri A SCHEMBL30132415 | 0.84 | KCNMA1 (0.64) | KLKB1EPHA2ELANEKCNA3KCNA1 | |
| SCHEMBL29362264 | 0.83 | PCSK9 (0.58) | KLKB1EPHA2ELANECHRNA7 | |
| Cycloviolacin O13 SCHEMBL30831409 | 0.83 | ELANE (0.71) | KLKB1EPHA2ELANECHRNA7 | |
| Cycloviolacin O2 SCHEMBL30497729 | 0.83 | KCNMA1 (0.62) | KLKB1EPHA2ELANEKCNA3KCNA1 | |
| SCHEMBL18375845 | 0.82 | EPHA2 (0.58) | KLKB1EPHA2ACEACE2TSLP | |
| SCHEMBL18375815 | 0.82 | EPHA2 (0.58) | KLKB1EPHA2ACEACE2TSLP | |
| Circulin F SCHEMBL29508763 | 0.82 | ELANE (0.69) | KLKB1EPHA2ELANECHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | TWINPIG BIOLAB INC. (KR) | 2026-01-01 | — | — | US | claimed |
| US-20250228951-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | TWINPIG BIOLAB INC. (KR) | 2025-07-17 | — | — | US | claimed |
| CN-112689758-B | Device and method for checking the effect of a drug on microorganisms | 上海宜晟生物科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| EP-4512410-A1 | NOVEL-PEPTIDE-BASED ANTICANCER IMMUNOTHERAPEUTIC AGENT | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| EP-4512411-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | Twinpig Biolab, Inc. (KR) | 2025-02-26 | — | — | EP | claimed |
| CN-118453517-B | Composition for targeted binding of LDLR and application thereof | 杭州珞米医疗科技有限公司 | 2024-10-08 | — | — | CN | claimed |
| EP-3554532-B1 | HBD2 FOR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS OF THE LUNGS | DEFENSIN THERAPEUTICS APS (DK) | 2024-09-25 | — | — | EP | claimed |
| CN-118453517-A | Composition for targeted binding of LDLR and application thereof | 杭州珞米医疗科技有限公司 | 2024-08-09 | — | — | CN | claimed |
| WO-2023195805-A9 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | 트윈피그바이오랩(주) | 2024-07-11 | — | — | WO | claimed |
| WO-2023195805-A2 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | 트윈피그바이오랩(주) | 2023-10-12 | — | — | WO | claimed |
| US-11725227-B2 | Devices and methods for examining drug effects on microorganisms | ESSENLIX CORPORATION (US) | 2023-08-15 | — | — | US | claimed |
| CN-116087515-A | Biomarker combinations for gastric cancer diagnosis | 复旦大学附属中山医院 | 2023-05-09 | — | — | CN | claimed |
| US-20230067261-A1 | METHODS FOR TREATING INFLAMMATORY CONDITIONS OF THE LUNGS | DEFENSIN THERAPEUTICS APS (DK) | 2023-03-02 | — | — | US | claimed |
| EP-4103585-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | Twinpig Biolab, Inc. (KR) | 2022-12-21 | — | — | EP | claimed |
| US-20220354957-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | US | claimed |
| WO-2022234346-A1 | PEPTIDES TARGETING MACROPHAGES, AND CONJUGATES, COMPOSITIONS, AND USES THEREOF | TWINPIG BIOLAB, INC. (KR) | 2022-11-10 | — | — | WO | claimed |
| US-11484601-B2 | Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide | TWINPIGBIOLAB INC. (KR) | 2022-11-01 | — | — | US | claimed |
| US-11413328-B2 | Methods for treating inflammatory conditions of the lungs | NOVOZYMES A/S (DK) | 2022-08-16 | — | — | US | claimed |
| US-20220175848-A1 | METHODS AND COMPOSITIONS FOR CELL THERAPY | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000782-A1 | ITGB2-MEDIATED DRUG DELIVERY SYSTEM | ITGB8, ITGB2, ITGA8 | KLKB1 229/4885EPHA2 128/4885ELANE 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.